PLK1 and breast carcinoma: Our preclinical studies demonstrate the synergistic efficacy of the PI3Kα inhibitor alpelisib and the PLK1 inhibitor onvansertib in PIK3CA-mutant HR+ breast cancer cell lines and PDXs that are resistant to ET and palbociclib.